Rajpal Chopra, MD
Endocrinology, Diabetes & Metabolism · Flushing, NYNPI 1376562835
Payments from drug & device makers
Across 183 payments — averaging $25.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$738
- Boehringer Ingelheim$598
- Novo Nordisk$550
- Xeris Pharmaceuticals, Inc.$430
- Abbott$344
- Medtronic$339
- plus $2K from 22 others
What the payments were for
- Travel & lodging$220%
- Food & beverage$4,57298%
- Education$631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 37 | $738 |
| Boehringer Ingelheim | 22 | $598 |
| Novo Nordisk | 22 | $550 |
| Xeris Pharmaceuticals, Inc. | 20 | $430 |
| Abbott | 13 | $344 |
| Medtronic | 10 | $339 |
| Amgen(2 entities) | 12 | $268 |
| Cequr Corporation | 3 | $246 |
| AstraZeneca | 3 | $229 |
| Mannkind Corporation | 6 | $133 |
| Dexcom, Inc. | 6 | $133 |
| Paratek Pharmaceuticals, Inc. | 5 | $117 |
| Madrigal Pharmaceuticals | 3 | $84 |
| Corcept Therapeutics | 3 | $74 |
| Merck | 3 | $62 |
| Viiv Healthcare Company | 3 | $61 |
| Lexicon Pharmaceuticals, Inc. | 1 | $25 |
| Melinta Therapeutics, LLC | 1 | $25 |
| Radius Health, Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| BETA Bionics, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Insulet Corporation | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Tolmar, Inc. | 1 | $17 |
| Tandem Diabetes Care, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$152
- RYBELSUS$125
- FARXIGA$120
- CeQur Simplicity$111
How this compares
$4,657 in reported general payments places this provider in the 65th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 289 | $266,741 |
| MounjaroTirzepatide | 187 | $214,773 |
| OzempicSemaglutide | 179 | $184,379 |
| TrulicityDulaglutide | 129 | $149,290 |
| JanuviaSitagliptin Phosphate | 38 | $52,517 |
| FarxigaDapagliflozin Propanediol | 28 | $39,508 |
| TradjentaLinagliptin | 43 | $28,534 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $20,626 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 55 | $18,946 |
| Novolog FlexpenInsulin Aspart | 96 | $17,926 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $13,376 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $9,676 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $9,660 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 43 | $6,731 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 35 | $6,626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $738 | $364,063316 claims |
| Boehringer IngelheimJardiance, Tradjenta | $598 | $295,275332 claims |
| Novo NordiskOzempic | $550 | $184,379179 claims |
| MerckJanuvia, Janumet | $62 | $65,89351 claims |
| AstraZenecaFarxiga | $229 | $39,50828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Flushing
- Kalpana ReddyFlushing$470K
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Kenneth HershonNew Hyde Park$1.9M
- Michael ShanikSmithtown$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.